Nitresan (Nitrendipine)

Nitrendipine, the active ingredient in Nitresan, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering peripheral vascular resistance. GNH USA supplies Nitresan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitresan is a dihydropyridine calcium channel blocker indicated for conditions affecting systemic blood pressure. - Hypertension: reduces elevated blood pressure and helps prevent cardiovascular complications. - Essential hypertension: provides long‑term control of primary high blood pressure. - Isolated systolic hypertension: lowers systolic pressure in patients with age‑related arterial stiffness.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, especially after the first dose. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, particularly when standing. - Tachycardia: increased heart rate as a reflex response. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Severe bradycardia: markedly slow heart rate.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Hepatic impairment: use with caution and adjust dose if liver function is compromised. - Elderly patients: start at lower dose and monitor for orthostatic effects. - CYP3A4 inhibitors: avoid concomitant strong inhibitors that may raise drug levels. - Store below 25°C: keep in the original pack, protect from moisture.

Nitrendipine may interact with several drug classes, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Concomitant antihypertensives: risk of additive hypotensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations. - Grapefruit juice: may elevate drug exposure and precipitate hypotension. Moderate Interactions (Monitor Closely): - Calcium supplements or antacids: can reduce oral absorption. - Diuretics: may enhance blood‑pressure lowering effect. - Beta‑blockers: may mask reflex tachycardia and require monitoring.